



## ABOUT AMGEN

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients, but will also help reduce the social and economic burden of disease in society today.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology innovator since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

## INNOVATIVE MEDICINES

We have a presence in approximately 100 countries worldwide and our innovative medicines have reached millions of people in the fight against serious illnesses. We focus on the following therapeutic areas: oncology, nephrology, bone health and cardiovascular disease. Our medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

## TRANSFORMATIVE RESEARCH

Understanding the fundamental biological mechanisms of disease is a defining feature of Amgen's discovery research efforts—and a major contributor to the development of Amgen's deep and broad pipeline of potential new medicines. Amgen's "biology first" approach permits its scientists to first explore the complex molecular pathways of disease before determining what type of medicine, or modality, is most likely to deliver optimal efficacy and safety. With the advances in human genetics, Amgen continues to shed new light on the molecular roots of disease. Amgen subsidiary deCODE Genetics, a global leader in human genetics, is a powerful differentiator, greatly improving how we identify and validate human disease targets.

## WORLD-CLASS BIOMANUFACTURING

The treatment of millions of seriously ill patients worldwide depends on the safe and reliable production of biologic medicines. A worldwide leader in biologics manufacturing, Amgen has an outstanding track record of reliably delivering high-quality medicines to patients who need them. Significant skill, experience, vigilance and commitment are critical to help ensure the quality of a biologic medicine each time a new batch is made. At Amgen, robust quality control and a reliable supply of medicines for patients are every bit as important as scientific innovation.

### AMGEN MISSION

To serve patients

### AMGEN QUICK FACTS

#### Headquarters

Thousand Oaks, California

#### Staff

Nearly 20,000 worldwide

#### Stock Listing

NASDAQ: AMGN

#### Chairman and CEO

Robert A. Bradway

#### 2017 Financial Highlights

Total revenue: \$22.8 billion

Product sales: \$21.8 billion

R&D expense: \$3.6 billion

#### Address/Phone Amgen Netherlands

Amgen B.V.

Minervum 7061

4817 ZK BREDA

Phone: +31 (0)76 5732500

### PRODUCTS

AMGEVITA™ (adlimumab)

Aranesp® (darbepoetin alfa)

BLINCYTO® (blinatumomab)

KANJINTI™ (trastuzumab)

IMLYGIC® (talimogene laherparepvec)

Kyprolis® (carfilzomib)

Mimpara® (cinacalcet)

MVASI™ (bevacizumab)

Neulasta® (pegfilgrastim)

Neupogen® (filgrastim)

Nplate® (romiplostim)

Parsabiv™ (etelcalcetide)

Prolia® (denosumab)

Repatha® (evolocumab)

Vectibix® (panitumumab)

XGEVA® (denosumab)

For information: [www.amgen.nl](http://www.amgen.nl)



## THE AMGEN FOUNDATION

The Amgen Foundation seeks to advance excellence in science education to inspire the next generation of innovators, and invest in strengthening communities where Amgen staff members live and work. To date, the Foundation has donated more than \$250 million in grants to local, regional and international non-profit organizations that impact society in inspiring and innovative ways. The Amgen Foundation brings the excitement of discovery to the scientists of tomorrow through several signature programs, including Amgen Scholars, Amgen Biotech Experience and Amgen Teach. For more information, visit [www.AmgenInspires.com](http://www.AmgenInspires.com)

## AMGEN IN THE NETHERLANDS

Amgen Europe B.V. located in Breda since 1997, is responsible for distribution throughout Europe, Africa, the Middle East and a number of countries in other parts of the world. In Breda, our medicines are packed, labeled, combined with a country specific patient information leaflet and distributed. The marketing, sales and R&D organization ensuring the availability of our products in the Netherlands, Amgen B.V., is also located in Breda. In Breda, more than 500 employees work every day to serve every patient, every time by producing, selling and distributing our medicines and supporting clinical research on new innovations.

## REACHING PATIENTS WORLDWIDE

Amgen medicines help patients worldwide. We have with facilities or subsidiaries in the following locations:

<b>Europe</b>	Netherlands	<b>South America</b>	Lebanon
Austria	Norway	Argentina	Taiwan
Belgium	Poland	Brazil	Thailand
Bulgaria	Portugal	Colombia	United Arab Emirates
Czech Republic	Romania		Saudi Arabia
Croatia	Russia	<b>Africa</b>	Singapore
Denmark	Slovakia	Algeria	
Germany	Slovenia	Egypt	<b>Oceania</b>
Estonia	Spain	Marocco	Australia
Finland	Sweden	South Africa	New Zealand
France	Switzerland		
Greece	Turkey	<b>Asia</b>	
Hungary	United Kingdom	China	
Ireland		Hong Kong	
Iceland	<b>North America</b>	India	
Italy	Canada	Israel	
Latvia	Puerto Rico	Japan	
Lithuania	Mexico	Jordan	
Luxembourg	United States	Korea	